DOI : https://doi.org/10.18517/ijaseit.10.5.12502

Cowanin, a Cytotoxic Xanthone from Asam Kandis (Garcinia cowa, Roxb.) Reduced Cell Migration and Induced Cell Cycle Arrest on T47D Human Cancer Cell

Dira Hefni (1), - Dachriyanus (2), Fatma Sri Wahyuni (3), Eti Yerizel (4), Dessy Arisanty (5), Lusiana Nofita Yusra (6)
(1) Postgraduate Biomedical Science, Faculty of Medicine, Universitas Andalas, Padang, 25163, Sumatra Barat, Indonesia
(2) Faculty of Pharmacy, Universitas Andalas, Kampus Limau Manis, 25163, Padang, Sumatra Barat, Indonesia
(3) Faculty of Pharmacy, Universitas Andalas, Kampus Limau Manis, 25163, Padang, Sumatra Barat, Indonesia
(4) Faculty of Medicine, Universitas Andalas, Kampus Limau Manis, 25163, Padang, Sumatra Barat, Indonesia
(5) Faculty of Medicine, Universitas Andalas, Kampus Limau Manis, 25163, Padang, Sumatra Barat, Indonesia
(6) Faculty of Pharmacy, Universitas Andalas, Kampus Limau Manis, 25163, Padang, Sumatra Barat, Indonesia
Fulltext View | Download
How to cite (IJASEIT) :
Hefni, Dira, et al. “Cowanin, a Cytotoxic Xanthone from Asam Kandis (Garcinia Cowa, Roxb.) Reduced Cell Migration and Induced Cell Cycle Arrest on T47D Human Cancer Cell”. International Journal on Advanced Science, Engineering and Information Technology, vol. 10, no. 5, Oct. 2020, pp. 2164-9, doi:10.18517/ijaseit.10.5.12502.
Citation Format :
This study aims to investigate and evaluate the mechanism action of cowanin, a cytotoxic xanthone isolated from ethanolic extract of the stem bark of asam kandis (Garcinia cowa Roxb). This compound was isolated after successive column and radial chromatography to give a yellow needless crystal, m.p. 121-124 oC. Based on ultraviolet, infrared, mass and nuclear magnetic resonance spectroscopic data and comparison with those of the literature, this compound was elucidated as cowanin. Since it had activity against T47D human breast cancer cell lines, further investigation of its mechanism activity was performed to explore the effects of cowanin on cell viability, migration of cells, and the cell cycle activities against T47D breast cancer cells. Viability of cell was carried out by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, migration of cells by scratch migration assay, and the cell cycle analysis by flow cytometry method. As a result of this investigation, it can be seen that cowanin could inhibited T47D cells' growth at concentration 0.1, 1, 10, and 100 µg/ml at 48 hours with the IC50 value of 11.11 µg/ml. Cowanin exhibited inhibiting the cell migration T47D cells at concentration 11.1 μg/mL treated cells at 48 h was 0.32 fold compared to control, suggesting the potent inhibitory effect of it. Cowanin is caused in significant detention of T47D cells at the G0-G1 phase of the cell cycle. Based on these data, it can be concluded that cowanin is a potential candidate to be developed as an anticancer drug.

R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA. Cancer J. Clin., 2017, doi: 10.3322/caac.21387.

American Cancer Society, “Cancer Facts and Figures 2017,” Genes Dev., 2017, doi: 10.1101/gad.1593107.

C. J. Sherr and J. Bartek, “Cell Cycle-Targeted Cancer Therapies S phase: the DNA synthesis phase of the cell cycle,” Annu. Rev. Cancer Biol. 2017, 2017, doi: 10.1146/annurev-cancerbio-040716-075628.

C. Satyanarayana, D. S. Deevi, R. Rajagopalan, N. Srinivas, and S. Rajagopal, “DRF 3188 a novel semi-synthetic analog of andrographolide: Cellular response to MCF 7 breast cancer cells,” BMC Cancer, 2004, doi: 10.1186/1471-2407-4-26.

A. B. Da Rocha, R. M. Lopes, and G. Schwartsmann, “Natural products in anticancer therapy,” Current Opinion in Pharmacology. 2001, doi: 10.1016/S1471-4892(01)00063-7.

D. Wu and F. Lin, “Cell migration,” in Comprehensive Biotechnology, 2019.

Dachriyanus, D. Arbain, D. P. Putra, M. V. Sargent, R. Susila, and F. S. Wahyuni, “Indole alkaloids from two species of Ophiorrhiza,” Aust. J. Chem., 2000, doi: 10.1071/ch99112.

Dachriyanus, M. V. Sargent, and F. S. Wahyuni, “(+)-Isochimonanthine, a pyrrolidinoindole alkaloid from Argostemma yappii king,” Aust. J. Chem., 2000, doi: 10.1071/ch99114.

D. Arbain, L. T. Byrne, Dachriyanus, and M. V. Sargent, “Isomalindine-16-carboxylate, a zwitterionic alkaloid from Ophiorrhiza cf. communis,” Aust. J. Chem., 1997, doi: 10.1071/C97054.

D. Arbain, L. T. Byrne, Dachriyanus, N. Evrayoza, and M. V. Sargent, “Bracteatine, a quaternary glucoalkaloid from Ophiorrhiza bracteata,” Aust. J. Chem., 1997, doi: 10.1071/C97055.

F. S. Wahyuni et al., “A new ring-reduced tetraprenyltoluquinone and a prenylated xanthone from Garcinia cowa,” Aust. J. Chem., 2004, doi: 10.1071/CH03175.

F. S. Wahyuni, D. A. I. Ali, N. H. Lajis, and Dachriyanus, “Anti-inflammatory activity of isolated compounds from the Stem Bark of Garcinia cowa Roxb,” Pharmacogn. J., 2017, doi: 10.5530/pj.2017.1.10.

F. S. Wahyuni, J. Stanslas, N. H. Lajis, and Dachriyanus, “Cytotoxicity studies of tetraprelyltoluquinone, a prenilated hydroquinone from Garcina cowa Roxb on H-460, MCF-7 and DU-145,” Int. J. Pharm. Pharm. Sci., vol. 7, no. 3, pp. 60-63, 2015.

F. S. Wahyuni, K. Shaari, J. Stanslas, N. Lajis, and D. Hamidi, “Cytotoxic compounds from the leaves of Garcinia cowa Roxb,” J. Appl. Pharm. Sci., 2015, doi: 10.7324/JAPS.2015.50202.

P. Olszewska, D. Cal, P. Zagórski, and E. Mikiciuk-Olasik, “A novel trifluoromethyl 2-phosphonopyrrole analogue inhibits human cancer cell migration and growth by cell cycle arrest at G1 phase and apoptosis,” Eur. J. Pharmacol., 2020, doi: 10.1016/j.ejphar.2020.172943.

F. S. Wahyuni, K. Shaari, J. Stanslas, N. H. Lajis, and Dachriyanus, “Cytotoxic Xanthones from the Stem Bark of Garcinia cowa Roxb,” J. Chem. Pharm. Res., vol. 7, no. 1, pp. 227-236, 2015.

Z. Darzynkiewicz and H. Zhao, “Cell Cycle Analysis by Flow Cytometry,” in eLS, 2014.

P. Champelovier, A. Simon, C. Garrel, G. Levacher, V. Praloran, and D. Seigneurin, “Is interferon γ one key of metastatic potential increase in human bladder carcinoma?,” Clin. Cancer Res., 2003.

J. Buolamwini, “Cell Cycle Molecular Targets in Novel Anticancer Drug Discovery,” Curr. Pharm. Des., 2005, doi: 10.2174/1381612003400948.

M. E. Law, P. E. Corsino, S. Narayan, and B. K. Law, “Cyclin-dependent kinase inhibitors as anticancer therapeutics,” Mol. Pharmacol., 2015, doi: 10.1124/mol.115.099325.

C. Ito et al., “Xanthones as inhibitors of Epstein-Barr virus activation,” Cancer Lett., 1998, doi: 10.1016/S0304-3835(98)00173-6.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).